Lymphoma, Non-Hodgkin
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
A borderline significantly increased risk of NHL was also observed for CBS (rs1801181, Ex13+41C>T), FTHFD (rs2305230, Ex10-40G>T), SHMT1 (rs1979277, Ex12+138C>T), and SHMT1 (rs1979276, Ex12+236T>C), and these associations appeared to be contingent on dietary nutrient intakes.
|
23913011 |
2013 |
Lymphoma, Non-Hodgkin
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.
|
15198953 |
2004 |
Lymphoma, Non-Hodgkin
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
SHMT1 C1420T polymorphism may be associated with NHL risk, which needs to be validated in large, prospective studies.
|
26666829 |
2015 |
Lymphoma, Non-Hodgkin
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Meta-analysis for SNPs in the MTHFR, MTR, MTRR and SHMT revealed a reducing effect of the MTR 2756G allele on the risk of NHL (OR=0.902; 95% CI 0.821-0.991, P=0.03).
|
21055808 |
2011 |
Lymphoma, Non-Hodgkin
|
0.350 |
Biomarker
|
disease |
BEFREE |
Our study suggests that variation in several OCM genes (CBS, FTHFD, SHMT1, TCN1, and TYMS) may influence susceptibility to NHL.
|
25384508 |
2015 |
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
In the subgroup analysis based on ethnicity, SHMT1 C1420T polymorphism has shown a protective effect on breast cancer in Asians (T vs. C, OR = 0.78, 95 % CI = 0.66-0.93) but not in Caucasian (T/T vs. C/C, OR = 0.98, 95 % CI = 0.86-1.12).
|
24789272 |
2014 |
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Therefore, our meta-analysis suggested that the SHMT1 C1420T polymorphism was associated with decreased risk of breast cancer.
|
26125758 |
2015 |
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Conversely, for women over 50, the risk of breast cancer development was statistically associated with the MTHFR 677CT genotype, but especially significant was risk associated with the presence of the polymorphic allele of cSHMT C1420T (P = 0.0120) and the protective effect associated with the RFC1 G80A polymorphism allele (P = 0.0021), was restrict to this age group.
|
22134752 |
2012 |
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
There was no evidence of an association between the cSHMT genotype and breast cancer occurrence.
|
19707223 |
2010 |
Breast Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Conversely, for women over 50, the risk of breast cancer development was statistically associated with the MTHFR 677CT genotype, but especially significant was risk associated with the presence of the polymorphic allele of cSHMT C1420T (P = 0.0120) and the protective effect associated with the RFC1 G80A polymorphism allele (P = 0.0021), was restrict to this age group.
|
22134752 |
2012 |
Breast Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
In the subgroup analysis based on ethnicity, SHMT1 C1420T polymorphism has shown a protective effect on breast cancer in Asians (T vs. C, OR = 0.78, 95 % CI = 0.66-0.93) but not in Caucasian (T/T vs. C/C, OR = 0.98, 95 % CI = 0.86-1.12).
|
24789272 |
2014 |
Breast Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
There was no evidence of an association between the cSHMT genotype and breast cancer occurrence.
|
19707223 |
2010 |
Breast Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Therefore, our meta-analysis suggested that the SHMT1 C1420T polymorphism was associated with decreased risk of breast cancer.
|
26125758 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.330 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-198 suppressed proliferation of lung adenocarcinoma cells both in vitro and in vivo by directly targeting SHMT1. miR-198 may be a potential therapeutic target for lung adenocarcinoma in the near future.
|
26553359 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.330 |
Biomarker
|
disease |
BEFREE |
In conclusion, we demonstrate that hsa_circ_0025036 regulates cell proliferation and apoptosis in lung adenocarcinoma cells probably via hsa_circ_0025036/miR-198/SHMT1&TGF-α axis. hsa_circ_0025036 may serve as a potential prognostic biomarker and a therapeutic target for lung adenocarcinoma.
|
30138108 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.330 |
Biomarker
|
disease |
BEFREE |
miR-218-5p was enhanced and SHMT1 was inhibited in NK cells of LA patients, whereas stimulation of interleukin-2 (IL-2) reversed their abundances.
|
31124332 |
2019 |
Schizophrenia
|
0.310 |
Biomarker
|
disease |
BEFREE |
These results suggest that Shmt1 (SHMT1), but not Srr, is likely to be one of the genetic components regulating PPI in mice and possibly relevant to schizophrenia.
|
20977478 |
2010 |
Lymphoma, Non-Hodgkin, Familial
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
SHMT1 C1420T polymorphism contributes to the risk of non-Hodgkin lymphoma: evidence from 7309 patients.
|
26666829 |
2015 |
Malignant Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
In summary, the findings suggest that SHMT1 C1420T polymorphism is not associated with overall cancer development, but might decrease cancer susceptibility of Asians as well as reduce leukemia risk.
|
24716966 |
2014 |
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Serine hydroxymethyltransferase 1 (SHMT1) is recently found to play critical roles in human cancers including lung cancer, ovarian cancer and intestinal cancer.
|
30755243 |
2019 |
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
This study illustrates how silencing the SHMT1 expression inhibits cancer growth and the increased VB6 channeling for sustenance of cancer cells promotes VB6-coupled vector to elicit enhanced delivery of siSHMT1.
|
25132602 |
2014 |
Malignant Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
The results showed that there was no association between SHMT1 C1420T polymorphism and cancer risk.
|
25194438 |
2014 |
Malignant Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
SHMT1 C1420T may lead to the abnormal biosynthesis involved in DNA synthesis and methylation, and it may eventually increase cancer susceptibility.
|
26666829 |
2015 |
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
It is obvious that SHMT plays an indispensable role in nucleic acid biosynthesis; therefore, designing and developing a repressor/inhibitor of the SHMT gene/protein may resolve the problem of drug resistance to cancer chemotherapy.
|
15044825 |
2003 |
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
These results demonstrate that MTHFD1 and SHMT1, which are key enzymes providing one-carbon units for dTMP biosynthesis in the form of 5,10-methylenetetrahydrofolate, are direct targets of As<sub>2</sub>O<sub>3</sub>-induced proteolytic degradation, providing a mechanism for arsenic in the etiology of cancer and developmental anomalies.
|
28265077 |
2017 |